Table 2.
Leakage, EVAC and transanal closure characteristics
| CLEAN study patients (n = 30) | Start Endosponge® therapy | ||
|---|---|---|---|
| <3 weeks (N = 15) | >3 weeks (N = 15) | ||
| Location of leakage (assessed during transanal closure) | |||
| Ventral | 4 (13%) | 1 (7%) | 3 (20%) |
| Dorsal | 22 (73%) | 10 (67%) | 12 (80%) |
| Lateral | 2 (7%) | 2 (13%) | 0 |
| Complete dehiscence | 2 (7%) | 2 (13%) | 0 |
| Median time (days, range) from surgery to diagnose leak | 14 (3–75) | 9 (3–14) | 24 (3–75) |
| Median time (days, range) from surgery to start Endosponge® | 23 (3–158) | 13 (3–21) | 34 (25–158) |
| Duration Endosponge® therapy prior to early transanal closure in days (median, range) | 13 (5–51) | 12 (6–51) | 13 (5–44) |
| Number of Endosponge® procedures prior to transanal closure (median, range) | 3.5 (2–15) | 3 (2–15) | 4 (2–13) |
| Patients requiring Endosponge® post transanal closure | 13 (43%) | 5 (33%) | 8 (53%) |
| Defect closure confirmed at first imaging endoscopy after transanal surgery (%, n) | 2 (7%) | 1 (7%) | 1 (7%) |
Evac vacuum-assisted drainage